Literature DB >> 7123157

In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma.

D Peest, G Holm, H Mellstedt, D Pettersson.   

Abstract

The in vitro monoclonal and polyclonal immunoglobulin (Ig) production of peripheral blood mononuclear cells was studied in human multiple myeloma (four IgG myelomas, one IgA myeloma) and in one patient with benign monoclonal gammopathy. Using an enzyme-linked immunosorbent assay with anti-class-specific antisera and antisera against idiotypic structures on the myeloma protein, it was possible to quantitate separately monoclonal and polyclonal Ig of the same class in cell culture supernatants. After stimulation with pokeweed mitogen (PWM) patients' cells produced lower amounts of polyclonal Ig than cells from healthy adults. In contrast, production of monoclonal Ig could not be enhanced by PWM. Moreover, the kinetics of monoclonal Ig production was different from that of polyclonal Ig. Myeloma cells contained large amounts of monoclonal Ig while their content of polyclonal Ig was low. A rapid release of preformed monoclonal Ig during the first day of culture was not inhibited by puromycin. A later phase of release was partly suppressed by puromycin and was probably caused by active protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7123157     DOI: 10.1111/j.1365-3083.1982.tb00689.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

1.  Regulation of the in vitro monoclonal immunoglobulin production in cultures of peripheral blood mononuclear cells and bone marrow cells from myeloma patients mediated by T cell dependent mitogens.

Authors:  D Peest; S Gasch; C Thiele; B Bartels; U Brunkhorst; I Dallmann; M Hoffmann; I Schedel; H Deicher
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

2.  Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures.

Authors:  D Peest; R Hölscher; R Weber; R Leo; H Deicher
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

3.  Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections.

Authors:  G A Linde; L Hammarström; M A Persson; C I Smith; V A Sundqvist; B Wahren
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

4.  Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura.

Authors:  J Winiarski; G Holm
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

5.  Effect of interleukin-2 on the ex vivo growth of human myeloma cells.

Authors:  D Peest; I de Vries; R Hölscher; R Leo; H Deicher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Analysis of T-cell cultures and clones from a patient with classic rheumatoid arthritis--evidence for the existence of autoreactive T-cell clones in blood and synovial fluid.

Authors:  M Schlesier; C Ramb-Lindhauer; M Gärtner; H H Peter
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

7.  Imbalances of T-cell subsets in monoclonal gammopathies.

Authors:  L Bergmann; P S Mitrou; K C Weber; W Kelker
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Selective induction of light chain synthesis in cultures of blood lymphocytes from patients with IgG myelomatosis.

Authors:  L A Walker; G D Johnson; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

9.  Serum antibodies against common antigens of bacterial lipopolysaccharides in healthy adults and in patients with multiple myeloma.

Authors:  C Stoll; I Schedel; D Peest
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

10.  Cytostatic drug sensitivity test for human multiple myeloma, measuring monoclonal immunoglobulin produced by bone marrow cells in vitro.

Authors:  D Peest; B Bartels; I Dallmann; I Schedel; H Deicher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.